Rethinking yeast vacuoles as antiviral agents and versatile biological platforms for biotechnology.

The search for safe and sustainable antiviral strategies has intensified as concerns grow over ecological and health impacts of conventional disinfectants. In a recent study, T. Kim, J.-H. Jeong, Y.-H. Kim, and J. Min (Microbiol Spectr 14:e02886-25, 2026, https://doi.org/10.1128/spectrum.02886-25) demonstrate that vacuoles from Saccharomyces cerevisiae exhibit measurable antiviral activity against the non-enveloped bacteriophage T4. They show that vacuoles reduce viral infectivity in a concentration- and time-dependent manner and induce structural damage, including separation of the capsid and tail. Notably, storage conditions modulate efficacy, with pellet-stored vacuoles displaying enhanced antiviral activity linked to physicochemical changes. While prior studies have demonstrated the activity of yeast-derived vacuoles against enveloped viruses, this work expands their antiviral function. These observations position yeast-derived vacuoles as a biologically inspired antiviral platform. Here, I contextualize these findings within the broader field of antivirals, discuss mechanistic and biological implications, and highlight key opportunities for translating this concept into practical antiviral and biotechnological applications.